1-(pyridin-3-yl)piperidin-4-ol | 1516560-40-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-(pyridin-3-yl)piperidin-4-ol
• 英文别名: 1-pyridin-3-ylpiperidin-4-ol
• CAS: 1516560-40-9
• 化学式: C₁₀H₁₄N₂O
• 分子量: 178.234
• InChiKey: UTCZEZIPWBTXDC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  36.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(pyridin-3-yl)piperidin-4-ol 在 吡啶 、 4-二甲氨基吡啶 、 caesium carbonate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 32.0h， 生成
  参考文献：
  名称：

  Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists

  摘要：

  G protein-coupled receptor 40 (GPR40) has become an attractive target for the treatment of diabetes since it was shown clinically to promote,glucose-stimulated insulin secretion. Herein, we report our efforts to develop highly I selectiveand potent GPR40 agonists with a dual mechanism of action, promoting both ghicose-clependent insulin and incretin secretion. Employing strategies to increase fiolarity and the ratio of sp(3)/sP(2) character of the chemotype, we identified BMS-986118 (compound 4), which showed potent and selective GPR40 agonist activity in vitro. In vivo, compound 4 demonstrated insulinotropic efficacy and GLP-1 secretory effects resulting in improved glucose control in acute animal models.

  DOI：

  10.1021/acs.jmedchem.7b00982
• 作为产物：
  描述：

  4-羟基哌啶 、 3-溴吡啶 在 氯(2-二环己基膦基-2',4′,6′-三异丙基-1,1′-联苯基)[2-(2-氨基乙基)苯基)]钯(II) 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 为溶剂， 反应 2.5h， 生成 1-(pyridin-3-yl)piperidin-4-ol
  参考文献：
  名称：

  Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists

  摘要：

  G protein-coupled receptor 40 (GPR40) has become an attractive target for the treatment of diabetes since it was shown clinically to promote,glucose-stimulated insulin secretion. Herein, we report our efforts to develop highly I selectiveand potent GPR40 agonists with a dual mechanism of action, promoting both ghicose-clependent insulin and incretin secretion. Employing strategies to increase fiolarity and the ratio of sp(3)/sP(2) character of the chemotype, we identified BMS-986118 (compound 4), which showed potent and selective GPR40 agonist activity in vitro. In vivo, compound 4 demonstrated insulinotropic efficacy and GLP-1 secretory effects resulting in improved glucose control in acute animal models.

  DOI：

  10.1021/acs.jmedchem.7b00982

文献信息

• Nucleophilic amination of methoxypyridines by a sodium hydride–iodide composite
  作者：Jia Hao Pang、Atsushi Kaga、Shunsuke Chiba

  DOI：10.1039/c8cc05979a

  日期：——

  A new protocol for nucleophilic amination of methoxypyridines and their derivatives was developed using sodium hydride (NaH) in the presence of lithium iodide (LiI). The method offers a concise access to various aminopyridines which are potentially of medicinal interest.

  在碘化锂（LiI）存在下，使用氢化钠（NaH）开发了甲氧基吡啶及其衍生物亲核胺化的新方案。该方法提供了对可能具有医学意义的各种氨基吡啶的简洁途径。
• 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives
  申请人：Gruenenthal GmbH

  公开号：US20180201616A1

  公开（公告）日：2018-07-19

  The invention relates to 3-((hetero-)aryl)-8-amino-2-oxo-1,3 -diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.